OTCPK:CLVS.F

Stock Analysis Report

Executive Summary

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden and internationally.

Snowflake

Fundamentals

Flawless balance sheet with solid track record.

Risks

  • CellaVision is covered by less than 3 analysts.

Share Price & News

How has CellaVision's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

16.9%

CLVS.F

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

n/a

CLVS.F

9.5%

US Medical Equipment

1.1%

US Market

No trading data on CLVS.F.

No trading data on CLVS.F.


Share holder returns

CLVS.FIndustryMarket
7 Day16.9%0.7%-0.2%
30 Day-9.1%0.1%2.5%
90 Dayn/a2.5%1.6%
1 Yearn/a10.4%9.5%3.4%1.1%
3 Yearn/a69.3%64.1%45.2%35.8%
5 Yearn/a138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is CellaVision's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CellaVision undervalued based on future cash flows and its price relative to the stock market?

86.61x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

CellaVision's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

CellaVision's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

CellaVision is overvalued based on earnings compared to the US Medical Equipment industry average.

CellaVision is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

CellaVision is poor value based on expected growth next year.


Price Based on Value of Assets

CellaVision is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is CellaVision expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

18.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

CellaVision's revenue is expected to grow by 15.5% yearly, however this is not considered high growth (20% yearly).

CellaVision's earnings are expected to grow by 18.3% yearly, however this is not considered high growth (20% yearly).

CellaVision's revenue growth is expected to exceed the United States of America market average.

CellaVision's earnings growth is expected to exceed the United States of America market average.

CellaVision's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

CellaVision is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has CellaVision performed over the past 5 years?

20.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

CellaVision has delivered over 20% year on year earnings growth in the past 5 years.

CellaVision's 1-year earnings growth exceeds its 5-year average (54.3% vs 20.8%)

CellaVision's earnings growth has exceeded the US Medical Equipment industry average in the past year (54.3% vs 28.2%).


Return on Equity

CellaVision has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

CellaVision used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

CellaVision's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is CellaVision's financial position?


Financial Position Analysis

CellaVision is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

CellaVision's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

CellaVision has no debt.

CellaVision currently has no debt however we can't compare to 5 years ago as we have no data for that period.

CellaVision has no debt, it does not need to be covered by operating cash flow.

CellaVision has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

CellaVision has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is CellaVision's current dividend yield, its reliability and sustainability?

0.54%

Expected Dividend Yield


Dividend Yield and Payments Analysis

CellaVision's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

CellaVision's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

CellaVision is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

CellaVision is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of CellaVision's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

No need to calculate the sustainability of CellaVision's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of CellaVision's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average board tenure


CEO

Zlatko Rihter (49yo)

4.7yrs

Tenure

0

Mr. Zlatko Rihter has been the Chief Executive Officer and President of CellaVision AB since January 1, 2015. Mr. Rihter joined CellaVision in 2015. He served as an Executive Vice President of Global Sales ...


Board Age and Tenure

4.3yrs

Average Tenure

55yo

Average Age

The tenure for the CellaVision board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Christer Fåhraeus (54yo)

    Founder & Director

    • Tenure: 25.7yrs
    • Compensation: kr193.00k
  • Peter Wilson (52yo)

    Vice President of Global Marketing

    • Tenure: 0yrs
  • Maria Morin (45yo)

    VP of HR & Corporate Communications

    • Tenure: 0yrs
  • Magnus Blixt (53yo)

    Chief Financial Officer

    • Tenure: 6.3yrs
  • Zlatko Rihter (49yo)

    President & CEO

    • Tenure: 4.7yrs
  • Mattias Lundin (51yo)

    Vice President of Global Sales

    • Tenure: 0yrs

Board Members

  • Christer Fåhraeus (54yo)

    Founder & Director

    • Tenure: 25.7yrs
    • Compensation: kr193.00k
  • Anna Bernsten (58yo)

    Director

    • Tenure: 9.4yrs
    • Compensation: kr207.00k
  • Sören Mellstig (68yo)

    Chairman of the Board

    • Tenure: 3.7yrs
    • Compensation: kr494.00k
  • Åsa Hedin (57yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: kr213.00k
  • Niklas Prager (49yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: kr227.00k
  • Stefan Wolf (55yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: kr133.00k
  • Jürgen Riedl (42yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: kr133.00k

Company Information

CellaVision AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CellaVision AB (publ)
  • Ticker: CLVS.F
  • Exchange: OTCPK
  • Founded: 1994
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr9.004b
  • Listing Market Cap: kr928.111m
  • Shares outstanding: 23.85m
  • Website: https://www.cellavision.com

Number of Employees


Location

  • CellaVision AB (publ)
  • Mobilvägen 12
  • Lund
  • Skåne County
  • 223 62
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CEVIOM (OMX Nordic Exchange Stockholm)YesRegistered SharesSESEKMay 2007
CLVS.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDMay 2007
0MR5LSE (London Stock Exchange)YesRegistered SharesGBSEKMay 2007
CEVISBATS-CHIXE (BATS 'Chi-X Europe')YesRegistered SharesGBSEKMay 2007
C26DB (Deutsche Boerse AG)YesRegistered SharesDEEURMay 2007

Biography

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden and internationally. It offers analyzers, supplementary software, and  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:57
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.